131 related articles for article (PubMed ID: 28419449)
1. Pharmacogenetic association with neurotoxicity in Hispanic children with acute lymphoblastic leukaemia.
McClain CA; Bernhardt MB; Berger A; Bernini JC; Marquez-Do D; Winslow R; Scheurer ME; Schafer ES
Br J Haematol; 2018 Jun; 181(5):684-687. PubMed ID: 28419449
[No Abstract] [Full Text] [Related]
2. Association of CYP3A5 Expression and Vincristine Neurotoxicity in Pediatric Malignancies in Turkish Population.
Kayilioğlu H; Kocak U; Kan Karaer D; Percin EF; Sal E; Tekkesin F; Isik M; Oner N; Belen FB; Yilmaz Keskin E; Okur A; Albayrak M; Kaya Z; Pinarli FG; Yenicesu I; Karadeniz C; Oguz A; Gursel T
J Pediatr Hematol Oncol; 2017 Aug; 39(6):458-462. PubMed ID: 28697165
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: a single institution study.
Zgheib NK; Ghanem KM; Tamim H; Aridi C; Shahine R; Tarek N; Saab R; Abboud MR; El-Solh H; Muwakkit SA
Pharmacogenet Genomics; 2018 Aug; 28(8):189-195. PubMed ID: 30119132
[TBL] [Abstract][Full Text] [Related]
4. Variants in vincristine pharmacodynamic genes involved in neurotoxicity at induction phase in the therapy of pediatric acute lymphoblastic leukemia.
Martin-Guerrero I; Gutierrez-Camino A; Echebarria-Barona A; Astigarraga I; Garcia de Andoin N; Navajas A; Garcia-Orad A
Pharmacogenomics J; 2019 Dec; 19(6):564-569. PubMed ID: 30723315
[TBL] [Abstract][Full Text] [Related]
5. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia.
Egbelakin A; Ferguson MJ; MacGill EA; Lehmann AS; Topletz AR; Quinney SK; Li L; McCammack KC; Hall SD; Renbarger JL
Pediatr Blood Cancer; 2011 Mar; 56(3):361-7. PubMed ID: 21225912
[TBL] [Abstract][Full Text] [Related]
6. The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia.
Sims RP
J Oncol Pharm Pract; 2016 Feb; 22(1):76-81. PubMed ID: 25305360
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia.
Ceppi F; Langlois-Pelletier C; Gagné V; Rousseau J; Ciolino C; De Lorenzo S; Kevin KM; Cijov D; Sallan SE; Silverman LB; Neuberg D; Kutok JL; Sinnett D; Laverdière C; Krajinovic M
Pharmacogenomics; 2014 Jun; 15(8):1105-16. PubMed ID: 25084203
[TBL] [Abstract][Full Text] [Related]
8. Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach.
Moore AS; Norris R; Price G; Nguyen T; Ni M; George R; van Breda K; Duley J; Charles B; Pinkerton R
J Paediatr Child Health; 2011 Dec; 47(12):875-82. PubMed ID: 21658147
[TBL] [Abstract][Full Text] [Related]
9. Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia.
Lopez-Lopez E; Gutierrez-Camino A; Astigarraga I; Navajas A; Echebarria-Barona A; Garcia-Miguel P; Garcia de Andoin N; Lobo C; Guerra-Merino I; Martin-Guerrero I; Garcia-Orad A
Pharmacogenomics; 2016 May; 17(7):731-41. PubMed ID: 27180762
[TBL] [Abstract][Full Text] [Related]
10. Vincristine-induced peripheral neuropathy in survivors of childhood acute lymphoblastic leukaemia.
Tay CG; Lee VWM; Ong LC; Goh KJ; Ariffin H; Fong CY
Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28139029
[TBL] [Abstract][Full Text] [Related]
11. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.
Diouf B; Crews KR; Lew G; Pei D; Cheng C; Bao J; Zheng JJ; Yang W; Fan Y; Wheeler HE; Wing C; Delaney SM; Komatsu M; Paugh SW; McCorkle JR; Lu X; Winick NJ; Carroll WL; Loh ML; Hunger SP; Devidas M; Pui CH; Dolan ME; Relling MV; Evans WE
JAMA; 2015 Feb; 313(8):815-23. PubMed ID: 25710658
[TBL] [Abstract][Full Text] [Related]
12. Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients.
Renbarger JL; McCammack KC; Rouse CE; Hall SD
Pediatr Blood Cancer; 2008 Apr; 50(4):769-71. PubMed ID: 18085684
[TBL] [Abstract][Full Text] [Related]
13. Incidence of vincristine induced neurotoxicity in children with acute lymphoblastic leukemia and its correlation with nutritional deficiencies.
Dudeja S; Gupta S; Sharma S; Jain A; Sharma S; Jain P; Aneja S; Chandra J
Pediatr Hematol Oncol; 2019 Sep; 36(6):344-351. PubMed ID: 31514565
[TBL] [Abstract][Full Text] [Related]
14. Family-based exome-wide assessment of maternal genetic effects on susceptibility to childhood B-cell acute lymphoblastic leukemia in hispanics.
Archer NP; Perez-Andreu V; Scheurer ME; Rabin KR; Peckham-Gregory EC; Plon SE; Zabriskie RC; De Alarcon PA; Fernandez KS; Najera CR; Yang JJ; Antillon-Klussmann F; Lupo PJ
Cancer; 2016 Dec; 122(23):3697-3704. PubMed ID: 27529658
[TBL] [Abstract][Full Text] [Related]
15. Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia.
Gutierrez-Camino Á; Umerez M; Martin-Guerrero I; García de Andoin N; Santos B; Sastre A; Echebarria-Barona A; Astigarraga I; Navajas A; Garcia-Orad A
Pharmacogenomics J; 2018 Dec; 18(6):704-712. PubMed ID: 29282364
[TBL] [Abstract][Full Text] [Related]
16. The impact of CYP3A5*3 on risk and prognosis in childhood acute lymphoblastic leukemia.
Borst L; Wallerek S; Dalhoff K; Rasmussen KK; Wesenberg F; Wehner PS; Schmiegelow K
Eur J Haematol; 2011 Jun; 86(6):477-83. PubMed ID: 21418106
[TBL] [Abstract][Full Text] [Related]
17. Lack of association of the CEP72 rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population.
Gutierrez-Camino A; Martin-Guerrero I; Lopez-Lopez E; Echebarria-Barona A; Zabalza I; Ruiz I; Guerra-Merino I; Garcia-Orad A
Pharmacogenet Genomics; 2016 Feb; 26(2):100-2. PubMed ID: 26618658
[TBL] [Abstract][Full Text] [Related]
18. Presence of clone-specific markers at birth in children with acute lymphoblastic leukaemia.
Hjalgrim LL; Madsen HO; Melbye M; Jørgensen P; Christiansen M; Andersen MT; Pallisgaard N; Hokland P; Clausen N; Ryder LP; Schmiegelow K; Hjalgrim H
Br J Cancer; 2002 Oct; 87(9):994-9. PubMed ID: 12434291
[TBL] [Abstract][Full Text] [Related]
19. Effects of cytochrome P450 family 3 subfamily A member 5 gene polymorphisms on daunorubicin metabolism and adverse reactions in patients with acute leukemia.
Huang Z; Wang J; Qian J; Li Y; Xu Z; Chen M; Tong H
Mol Med Rep; 2017 Jun; 15(6):3493-3498. PubMed ID: 28440407
[TBL] [Abstract][Full Text] [Related]
20. Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma.
Sági JC; Egyed B; Kelemen A; Kutszegi N; Hegyi M; Gézsi A; Herlitschke MA; Rzepiel A; Fodor LE; Ottóffy G; Kovács GT; Erdélyi DJ; Szalai C; Semsei ÁF
BMC Cancer; 2018 Jul; 18(1):704. PubMed ID: 29970035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
